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Abstract: Coxsackievirus group B (CVB) contains six serotypes that can affect various organs. Some
of these organ-specific diseases such as myocarditis and pancreatitis can be caused by more than
one serotype. Thus, development of immunological tools common to multiple serotypes is desired.
This is especially critical for analyzing antigen-specific T cell responses at a single cell level. To this
end, we made efforts to identify the immunogenic epitopes of CVB3 leading us to localize three T
cell epitopes within the viral protein 1 (VP1) namely, VP1 681–700, VP1 721–740 and VP1 771–790.
First, we confirmed their immunogenicity in the immunization settings. Second, we sought to verify
the ability of VP1 epitopes to bind major histocompatibility complex (MHC) class II (IAk) molecules.
Third, we created MHC class II (IAk) dextramers and tetramers and ascertained the T cell responses
to be antigen-specific. Fourth, we analyzed the T cell responses in animals infected with CVB3 and
noted the magnitude of antigen-specific T cell responses occurring in the order of VP1 721–740 and
VP1 681–700 followed by VP1 771–790 as verified by proliferation assay and IAk tetramer staining.
All epitopes induced interferon (IFN)-γ as a major cytokine. Finally, we investigated whether the VP1
tools generated for CVB3 can also be used to verify T cell responses in infections caused by other
serotypes. To this end, we established the CVB4 infection model in A/J mice and found that the CVB4
infection led to the induction of IFN-γ-producing T cell responses primarily for VP1 721–740 and VP1
681–700. Thus, the VP1-specific tools, particularly IAk tetramers can be used to monitor anti-viral T
cell responses in multiple CVB serotypes.
Keywords: coxsackievirus B; myocarditis; MHC-tetramers; T cells
1. Introduction
Enteroviruses commonly cause infections in humans [1]. These are small (30 nm), non-enveloped,
positive-sense, single-stranded RNA viruses possessing an icosahedral capsid consisting of 60 subunits
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bearing four structural viral proteins (VPs): VP1 to VP4. The viral RNA is 7.5 kilo bases long, and the
coding region is encompassed by non-translated regions at both 5′ and 3′ ends. The genus Enterovirus
includes group A and group B coxsackieviruses. Within these, several serotypes have been identified
(23 in group A; six in group B). While some syndromes are caused only by group A coxsackieviruses,
diseases like myocarditis and pancreatitis are caused mainly by group B coxsackieviruses (CVB) [1–3].
Within the group B coxsackieviruses, CVB3 is commonly implicated in the causation of myocarditis.
CVB-reactive antibodies are found in ~50% of dilated cardiomyopathy (DCM) patients, while
enterovirus genomic material can be detected in up to 70% patients [4–8], suggesting CVB can
be an important trigger of myocarditis/DCM. Two phases of CVB3 infection have been described in the
mouse models that resemble human disease [9]. These include a viral/acute myocarditis phase (up to
14–18 days postinfection) and a nonviral/chronic myocarditis phase (beyond 18 days) [9]. In contrast
to CVB3, CVB4 is commonly linked with the development of type 1 diabetes (T1D) as evidenced by
serology, virus-recovery, and polymerase chain reaction (PCR) analysis [10–13]. Experimentally, CVB3
and CVB4 infections in young (4- to 6-week) non-obese diabetic (NOD) mice have been shown to
protect them from developing diabetes; in contrast, the same infections have been shown to augment
the disease in mice older than 12 weeks [14–16]. An emerging theme suggests that enteroviral
infections, in the face of preexisting insulitis, augment the development of diabetes through infiltration
of bystander immune cells, leading to destruction of insulin-producing pancreatic β islets. However,
in the absence of preexisting insulitis, virus infections favor the generation of regulatory T (Treg) cells
that can suppress diabetes development [14,17].
Because CVB infections are strongly associated with myocarditis and pancreatitis, and both
diseases can be triggered by more than one serotype, we sought to develop tools that allow us to
determine antigen-specific T cell responses in infections caused by multiple CVB serotypes. These
investigations led us to identify three epitopes within the CVB3 viral protein1 (VP1) that induce
varied degrees of T cell responses. By generating major histocompatibility complex (MHC) class
II/IAk dextramers and tetramers, we demonstrate that both CVB3 and CVB4 infections can lead to
the generation of interferon (IFN)-γ-producing, VP1-specific CD4 T cells, predominantly for VP1
721–740, suggesting that the VP1-specific tools, importantly, IAk tetramers, can be used to analyze
antigen-specific T cell responses in CVB infections.
2. Materials and Methods
2.1. Mice
Six to eight-week-old male and female A/J mice (H-2a) were procured from the Jackson Laboratory
(Bar Harbor, ME, USA) and maintained according to the institutional guidelines of the University of
Nebraska-Lincoln, Lincoln, NE. Approval for animal studies was granted by the Institutional Animal
Care and Use Committee, University of Nebraska-Lincoln (protocol #: 1398, approved January 3,
2017). Euthanasia was performed using a carbon dioxide chamber as recommended by the Panel on
Euthanasia, the American Veterinary Medical Association.
2.2. Peptide Synthesis and Immunization Procedures
An overlapping peptide library that included a total of 30 peptides of 20-mers was synthesized
by 9-fluorenylmethyloxycarbonyl chemistry. In addition, bovine ribonuclease (RNase) 43–56
(VNTFVHESLADVQA), biotinylated hen egg lysozyme (HEL) 46–61 (YNTDGSTDYGILQINSR)
(Neopeptide, Cambridge, MA) were also synthesized. All peptides were purified to be more than 90%
by high-performance liquid chromatography, and their identities were confirmed by mass spectroscopy.
Ultra-pure water was used to dissolve peptides and stored at −20 ◦C. For immunizations, VP1
peptides (VP1 681–700, VP1 721–740 and VP1 771–790) were individually emulsified in the complete
Freund’s adjuvant (CFA) containing Mycobacterium tuberculosis H37RA extract to a final concentration
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of 5 mg/mL(Difco Laboratories, Detroit, MI, USA). The peptide (100 µg per animal) emulsions were
administered subcutaneously into mice in the inguinal and sternum regions [18,19].
2.3. Virus Propagation and Infection
HeLa cells [American Type Culture Collection (ATCC), Manassas, VA, USA] were grown to 80%
to 90% confluence in 75 cm2 flasks in EMEM supplemented with 10% fetal calf serum (FCS). After
removing the medium, the adherent monolayer of cells were infected with CVB3 (Nancy strain, ATCC)
or CVB4 (E2 strain, kind gift from Dr. Shubhada Bopegamage, Slovak Medical University, Slovak
Republic) with multiplicity of infection 1 in EMEM containing no FCS. The virus was allowed to
adsorb to the cells by incubating the flasks at 37 ◦C for 1 h with gentle intermittent rotations every 10 to
15 min. Maintenance medium containing 2% FCS was then added and incubation was continued. After
confirming the cytopathic effect of virus, the infected culture flasks were subjected for three rounds of
freezing and thawing and culture supernatants containing virus were harvested by centrifuging cell
lysates at 6000 rpm for 10 min at 4 ◦C. The tissue culture infective dose (TCID50) values were then
determined according to Reed–Muench method. The virus stocks were aliquoted and preserved at
−80 ◦C until further use.
For infection studies, the virus stock was diluted in 1x phosphate-buffered saline (PBS) to contain
2000 to 10,000 TCID50/200 µl, and the inocula were administered into A/J mice intraperitoneally,
whereas the control (uninfected) mice received only 1x PBS. Animals were housed in filter-top cages
(two to three mice/cage) assembled with closed air-circulation. Cages containing the chow diet and
waterers were changed once every 3 days until the termination of the experiment, and the animals had
ad libitum access to food and water during the entire period of study. Animals were inspected twice a
day, and body weights were taken daily. Additionally, alternative food- and fluid-source, trans gel diet
(ClearH2O, Portland, ME, USA) were placed in the cage floor as needed. Hearts and pancreata were
collected from the animals that died naturally. At termination (days, 16 to 21 post-infection), animals
were euthanized using CO2 chamber prefilled with 2% CO2, and spleens, lymph nodes, hearts, and
pancreata were collected.
2.4. Proliferative Response
Lymph node cells (LNCs) and splenocytes obtained from animals on day 10 post-immunization
or infected animals at termination were used to assess their proliferative responses based on tritiated
3[H] thymidine-incorporation assay [20–22]. After stimulating the cells with indicated peptides for
2 days, and adding 3[H] thymidine (1 µci/well) during the next 16 h, proliferative responses were
measured as counts per minute (cpm). In some experiments, the T cell responses are shown as fold
changes derived by dividing the cpm values of cultures stimulated with peptides by the cpm values
of unstimulated cultures (medium controls). Similarly, to measure proliferative responses in CD4
and CD8 T cells, lymphocytes generated from animals immunized with VP1 peptides were used to
sort CD4 and CD8 T cells to a purity of more than 90% by negative selection using IMAG magnetic
separation kit as recommended by the manufacturer (BD Biosciences, San Jose, CA, USA) [19].
2.5. MHC Class II Binding
To determine the IAk-binding affinities of VP1 681–700, VP1 721–740 and VP1 771–790, we
used thrombin-cleaved, empty IAk molecules as we have described previously [23–25]. Cocktails of
individual reaction mixtures were prepared to include thrombin-cleaved IAk monomers (0.35 µg),
competitor peptides (VP1 681–700, VP1 721–740, VP1 771–790) [0.00001 µM to 100 µM], and a constant
amount of biotinylated reference peptide, HEL 46–61 (1 µM) [26,27]. The mixtures were incubated
at room temperature (RT) overnight. In parallel, anti-IAk (10 µg/mL) was coated onto 96-well white
fluorescence plates (Nunc, Rochester, NY, USA) in sodium phosphate 0.2 M, pH 6.8 overnight. After
a series of washing steps, the reaction mixtures described above were added in duplicates for each
peptide and incubated on a rocker at RT for 1 h and washed. Europium-labeled streptavidin (SA) was
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then added to a concentration of 1 µg/mL in dissociation-enhanced lanthanide fluoroimmunoassay
(DELFIA) buffer followed by DELFIA-enhancement solution (Perkin Elmer, Waltham, MA, USA).
After measuring the fluorescence intensities at excitation/emission wavelengths of 340/615 nm, the
half-maximal inhibitory concentration (IC50) values were then calculated as described [20–22].
2.6. Derivation of MHC Class II Dextramers and Tetramers
We adopted two approaches to create IAk dextramers and tetramers. In the first approach, we
derived IAk dextramers based on peptide-exchange reaction as we have described previously [25,28,29].
In brief, after biotinylation, the IAk/ MHC class II invariant chain-associated peptide (CLIP)
precursors were treated with thrombin to release CLIP, and the peptides (VP1 681–700, VP1 721–740
and VP1 771–790) were then loaded onto empty IAk molecules in peptide-exchange reactions
at a 3.3 to 66.6 µM ratio. The unincorporated peptides were eliminated using Amicon ultra
centrifugal filters (Millipore, Bellerica, MA, USA), and dextramers were then generated using
fluorophore-conjugated streptavidin (SA). In the second approach, IAk tetramers were derived
by using the IAk monomers in which the nucleotide (nt) sequences of VP1 681–700, VP1 721–740,
VP1 771–790 and RNase 43–56 were covalently tethered into the IAk-β construct such that the
peptide-linked monomers were expressed directly using the Baculovirus [30]. The nt sequences
were: VP1 681–700 (agagatcttgaactattatacacattggtcaggcagcataaagcttacgtttatgttctg), VP1 721–740
(tcctacaaaaagggttgatgccatgcttggtactcatgtagtttgggacgtggggctaca), VP1 771–790 (gtgctggtatcaaacaa
acatagtggtcccagcggatgcccaaagctcctgttacatcat) or RNase 43–56 (gtgaacacctttgtgcacgagtccctg
gctgatgtccaggcc). The soluble IAk molecules were then biotinylated, and tetramers were
derived by using the SA-fluorophore (PJ27S, Prozyme, Hayward, CA, USA) as we have described
previously [23,24].
2.7. Staining with Dextramers and Tetramers
LNCs and splenocytes obtained from mice immunized with VP1 681–700, VP1 721–740 and VP1
771–790 or mice infected with CVB3 or CVB4 were stimulated with the indicated peptides (20 µg/mL)
for 2 days, and after obtaining the viable cells by ficoll-paque density gradient centrifugation, cells were
maintained in medium containing interleukin (IL)-2. Cells were stained with dextramers or tetramers
during days 8 to 9 post-stimulations followed by anti-CD4 (GK1.5, Biolegend, San Diego, CA, USA)
and 7-aminoactinomycin D (7-AAD; Invitrogen, Carlsbad, CA, USA) as previously described [23,24,30].
After acquiring the cells by flow cytometry (FACSCalibur, BD Biosciences), percentages of dextramer
or tetramer positive cells were determined in the live (7-AAD¯) CD4+ subset using FlowJo software
(Tree Star, Ashland, OR, USA).
2.8. Cytokine Analysis
Supernatants were obtained from LNC and splenocyte cultures prepared from immunized animals
or CVB3 and CVB4-infected animals that were stimulated with or without VP1 681–700, VP1 721–740
and VP1 771–790, and RNase 43–56 (control) (20 µg/mL) on day 3 post-stimulations. Cytokine analysis
was performed using beads conjugated with capture and detection antibodies for a panel of T helper
(Th) 1, (IL-2, IFN-γ), Th2 (IL-4), and Th17 (IL-17A), including other inflammatory (IL-6 and tumor
necrosis factor, TNF-α) and anti-inflammatory (IL-10) cytokines as recommended by the manufacturer
(BD Biosciences). Briefly, capture bead/cytokine antibody conjugates were first prepared, and the
mixtures were added to a tube containing diluted standards or test samples, followed by the addition
of detection antibodies. After acquiring by flow cytometry, cytokine concentrations were determined
using the Flow cytometric analysis program (FCAP) Array Software (BD Biosciences).
2.9. Vβ Usage
LN and splenocytes were harvested from A/J mice infected with CVB3, and were stimulated
with the respective peptides for 2 days (20 µg/mL) and maintained in IL-2 medium. On day 4
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post-stimulation, cells were stained with a panel of anti-mouse TCR vβ antibodies: vβ 2, 4, 6, 7, 8.1, 8.2,
8.3, 9, 10b, 11, 12, 13, and 14 (BD Pharmingen), anti-CD4, and 7-AAD. After acquiring by flow cytometry,
percentages of TCR vβ+ CD4+ T cells were enumerated in the live (7-AAD¯) population [22,31].
2.10. Histology
Hearts and pancreata collected at termination were fixed in 10% phosphate-buffered formalin and
processed for the production of 5-µm-thick Hematoxylin and Eosin (H & E) serial sections, ~50 µm
apart from each other. All sections were examined by a board-certified pathologist blinded to treatment.
The total number of inflammatory cell foci was determined as reported previously [20,21].
2.11. Statistics
To analyze proliferative responses, baseline cpm values were derived by taking the average of the
cpm values of three replicates at zero concentrations. The adjusted cpm values were then calculated as
cpm values of test samples/baseline cpm values as a measure of response for test samples. Generalized
linear mixed models were used to analyze the data pertaining to treatment, concentrations, and body
weights. The data were analyzed using Proc Glimmix in SAS (Version 9.3, SAS Institute Inc., Cary,
NC, USA). For data sets, where normality assumptions were not satisfied, Friedman’s non-parametric
two-way ANOVA was used [32]. Tetramer+ cells were analyzed by student’s t-test. Barnard’s exact
test was used to analyze the histological parameters [33]. The data sets shown in the figures represent
the mean ± SEM values.
3. Results
3.1. CVB3 VP1 Contains Multiple Immunogenic Epitopes
To identify the immunogenic epitopes, we focused on the VP1, since this protein has been shown
to encompass antigenic determinants that induce antibody and T cell responses in other enteroviruses
such as Theiler’s murine encephalomyelitis virus (TMEV) and encephalomyocarditis virus [34–36].
We created an overlapping peptide library consisting of 30 peptides with 10 amino acids between
each (Table 1) and used them to stimulate splenocytes generated from A/J mice infected with CVB3
at 21 days post-infection based on 3[H] thymidine-incorporation assay. The expectation was that
the VP1-sensitized T cells generated in response to CVB3 should be able to respond to some of the
overlapping peptides. To capture these responses, we used RNase 43–56 as an irrelevant control. While,
we noted significant responses for VP1 681–700 (p ≤ 0.01) and VP1 771–790 (p ≤ 0.05), reactivity to VP1
721–740 was marginal (Figure 1). Although similar trends were noted for few other peptides localized
in the region, VP1 801–840, we did not pursue them for further characterization.
Table 1. List of CVB3 VP1 overlapping peptides
Peptide Sequence Peptide Sequence
VP1 571–590 GPVEDAITAAIGRVADTVGT VP1 721–740 PDKVDSYVWQTSTNPSVFWT
VP1 581–600 IGRVADTVGTGPNNSEAIPA VP1 731–750 TSTNPSVFWTEGNAPPRMSI
VP1 591–610 GPNNSEAIPALTAAETGHTS VP1 741–760 EGNAPPRMSIPFLSIGNAYS
VP1 601–620 LTAAETGHTSQVVPGDTMQT VP1 751–770 PFLSIGNAYSNFYDGWSEFS
VP1 611–630 QVVPGDTMQTRHVKNYHSRS VP1 761–780 NFYDGWSEFSRNGVYGINTL
VP1 621–640 RHVKNYHSRSESTIENFLCR VP1 771–790 RNGVYGINTLNNMGTLYARH
VP1 631–650 ESTIENFLCRSACVYFTEYE VP1 781–800 NNMGTLYARHVNAGSTGPIK
VP1 641–660 SACVYFTEYENSGAKRYAEW VP1 791–810 VNAGSTGPIKSTIRIYFKPK
VP1 651–670 NSGAKRYAEWVLTPRQAAQL VP1 801–820 STIRIYFKPKHVKAWIPRPP
VP1 661–680 VLTPRQAAQLRRKLEFFTYV VP1 811–830 HVKAWIPRPPRLCQYEKAKN
VP1 671–690 RRKLEFFTYVRFDLELTFVI VP1 821–840 RLCQYEKAKNVNFQPSGVTT
VP1 681–700 RFDLELTFVITSTQQPSTTQ VP1 831–850 VNFQPSGVTTTRQSITTMTN
VP1 691–710 TSTQQPSTTQNQDAQILTHQ VP1 841–860 TRQSITTMTNTGAIWTTIRG
VP1 701–720 NQDAQILTHQIMYVPPGGPV VP1 851–870 TGAIWTTIRGSVCGDYRVVN
VP1 711–730 IMYVPPGGPVPDKVDSYVWQ VP1 861–880 SVCGDYRVVNRHSATSADWQ
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3.2. VP1 Epitopes Induce Mainly CD4 T Cell Responses
To characterize antigen-specificity of T cell responses induced by VP1 epitopes, we examined
VP1 681–700, VP1 721–740 and VP1 771–790 by adopting an immunization strategy. LNCs obtained
from immunized animals were used to analyze recall responses to the immunizing peptides by using
RNase 43–56 as a control. The analysis revealed significant proliferative responses to VP1 681–700
(p ≤ 0.0001), VP1 721–740 (p ≤ 0.0001), and VP1 771–790 (p ≤ 0.001) (Figure 2a). Responses to all
the three peptides occurred dose-dependently, and the cells did not react to control (RNase 43–56),
suggesting that the responses obtained for each peptide are antigen-specific. We then asked whether
the responses are restricted to CD4 or CD8 T cells using the CD4 and CD8 T cells negatively sorted by
magnetic separation [19]. The data indicates that only the CD4, but not CD8 T cells, respond to each
peptide (Figure 2b) except that CD8 T cells in the VP1 681–700 group responded at 100 µg/mL that
might have been contributed by the residual CD4 T cells. Furthermore, by verifying the T cell responses
in naïve animals, we noted no significant responses to any of the three peptides, except a low-degree
of responses (~1.3-fold) were noted at a higher concentration of peptides for VP1 681–700 and VP1
721–740 (Figure S1). Thus, it is possible that the pre-existing repertoire of naïve antigen-reactive T cells
can possibly expand in response to immunizations.
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2 days, and after pulsing with 3[H] thymidine fo 16 h, proliferative responses were measured as
cpm. Representative data set obtained rom five individual experiments each involving hree to fiv
mice are shown. (b) Purified cells. LNCs obtained from ice immunized with VP1 681–700, VP1
721–740 and VP1 771–790, and CD4 and CD8 T cells w re enriched using negative selection by
Purified cells were stimula ed with the irradiated antigen presentin cells (APCs)/peptide
for 2 days. Aft r pulsing with 3[H] thymidine for 16 h, proliferative responses were mea ured as cpm.
Representative data set from two individual experime ts each involving three to five mice is shown. *
p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, and *** p ≤ 0. 001.
3.3. The VP1 Epitopes Bind IAk Molecules Differentially and the T Cell Responses Are Antigen-Specific
To determine the MHC-binding affinity of VP1 epitopes, we used empty IAk monomers as
described previously [22]. By using HEL 46–61 as a competitor reference [26,27,37], we analyzed
the binding ability of VP1 681–700, VP1 721–740 and VP1 771–790 and determined their IC50 values
(Figure 3a) [26,27,38]. We noted that the binding affinity of VP1 771–790 (IC50, 6.50 ± 0.27 µM) was
relatively stronger than VP1 721–740 (IC50, 41.50 ± 1.0 µM), whereas the IC50 value for VP1 681–700
was low (>100 µM). By relating these data to the T cell responses (Figure 2), it was apparent that the
VP1 681–700 indeed induced T cell response in spite of being a poor IAk-binder. The data suggest
that the poor MHC-binders do not necessarily mean that such epitopes do not induce T cell responses
in vivo. We then sought to characterize antigen specificity of VP1-reactive T cells by creating MHC
class II/IAk dextramers for all the three epitopes. Essentially, we generated empty IAk monomers
as we previously described [23,24,29], and after biotinylation, the IAk molecules were loaded with
VP1 681–700, VP1 721–740 and VP1 771–790 in a peptide-exchange reaction, which were then used
to generate dextramers after conjugating with SA-fluorophores. By using these reagents and control
dextramers (RNase 43–56), we performed the dextramer staining using T cell cultures generated for
each peptide. While, CD4 T cells in all the three cultures were found to bind the corresponding
dextramers, but not control, the dextramer staining intensity occurred in the order of VP1 721–740
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(5.93%) followed by VP1 771–790 (2.09%) and VP1 681–700 (0.95%) (Figure 3b). The data pointed to a
possibility that the VP1 epitopes may bind MHC class II molecules differentially.Viruses 2020, 12, x FOR PEER REVIEW 8 of 17 
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Figure 3. Determination of MHC-II binding affinities of VP1 epitopes and antigen-specificity of T
cell responses by MHC class II dextramer staining. (a) MHC-binding affinity. The reaction mixtures
containing thrombin-cleaved IAk monomers and competitor peptides VP1 681–700, VP1 721–740
and VP1 771–790, and biotinylated reference peptide, HEL 46–61, were individually prepared and
added in duplicates to fluorescence plates coated with anti-IAk. After washing and the addition
of europium-labeled streptavidin and DELFIA-enhancer, fluorescence intensities were measured at
excitation/emission wavelengths of 340/615 nm, and IC50 values were then calculated. Representative
dat from two individual experiments, each involving two replicates are shown. (b) Antigen-specificity.
Lymphocytes prepared from animals im unized w th indiv dual VP1 peptides (VP1 681–700, VP1
721–740 or VP1 771–790) were stimulat d with the corresponding peptides and were maintained in
medium supple ented with IL-2 for a week. Cells ere harvested between days 7–10 post-stimulation
and stained with indicated IAk/dextramers, anti-CD4 and 7-AAD. After acquiring the cells by flow
cytometry, dextramer positive cells were analyzed in the live (7-AAD¯) CD4 subset using FlowJo
software. Representative flow cytometric dot-plots for specific and control dextramers are shown in
the left panel. Data sets obtained from three individual experiments, each involving three to four mice
are shown in the right panel. RNase 43–56, control. ** p ≤ 0.01, and **** p ≤ 0.0001.
3.4. CVB3 Infection Leads to the Induction of VP1 Virus-Specific, CD4 T Cell Responses
The availability of three VP1 epitopes that induce varied T cell responses offered an advantage to
investigate the appearance of virus-specific T cells in CVB3 infection with an expectation that the T
cell reactivity can be obtained for at least one or more of these epitopes. We tested this hypothesis
by proliferation assay sing lymphocytes generated from CVB3-infected animals that w re later
stimulated with indivi ual VP1 peptides (VP1 681–700, P1 721–740 and VP1 771–790). We noted the
T cell responses to be dose-dependent, and significant for VP1 681–700 (p ≤ 0.0001) and VP1 721–740
(p ≤ 0.0001), but not for VP1 771–790 (Figure 4a). Expectedly, lymphocytes were non-responsive to
control (RNase 43–56). Additionally, based on TCR vβ analysis, we noted no striking differences with
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the use of specific vβ’s between any of the three peptide stimulations, and vβ-usage occurred in the
order of vβ8.1, 8.2 followed by others (vβ4, 6, 8.3, 10b, 14, 7, 2, 13, 12 and 9) (Figure S2). We then
determined antigen-specificity by creating the MHC class II tetramers (IAk), since the availability of
dextramers became limited. We also decided to generate fresh IAk monomers based on peptide-tethered
strategy, where the nucleotide sequences for VP1 681–700, VP1 721–740 and VP1 771–790 were tethered
into the IAk-β constructs as described previously [23,24,39]. After validating the tetramer reagents in
the immunization settings [22,23], we used them to stain lymphocytes prepared from CVB3-infected
mice (Figure 4b). While, the CD4 T cells reactive with VP1 681–700 and VP1 721–740 were found
to bind to their corresponding tetramers with the staining intensity for VP1 721–740 (3.20 ± 1.19 %,
p < 0.05) to be relatively higher than VP1 681–700 (0.64 ± 0.15 %, p < 0.05) tetramers, no appreciable
tetramer staining was evident for VP1 771–790 (0.64 ± 0.13 %) tetramers when compared with the
control tetramers (RNase 43–56). These data complement the patterns obtained in the proliferation
assay described above.
We then measured cytokine production in the culture supernatants obtained from lymphocyte
cultures stimulated with or without VP1 681–700, VP1 721–740 and VP1 771–790 by bead array analysis
for a panel of Th1, Th2, Th17 and other inflammatory (IL-6 and TNF-α) and anti-inflammatory (IL-10)
cytokines. While we detected the secretion of all cytokines tested except IL-4, their patterns varied
(Figure 4c). (a) The predominant cytokine observed in all the three peptide-stimulations was IFN-γ
(371 ± 18 to 388 ± 38 pg/mL). (b) In contrast to VP1 681–700 and VP1 771–790, we noted the detection
of other cytokines in VP1 721–740-stimulated cultures in the order of TNF-α (93 ± 6 pg/mL), IL-10
(92 ± 7 pg/mL), IL-6 (64 ± 15 pg/mL), IL-2 (32 ± 3 pg/mL), and IL-17A (9 ± 1 pg/mL). Since IFN-γ is
considered as a prototypic Th1 cytokine, and all the three peptides induced IFN-γ, we propose that the
IFN-γ-producing virus-reactive T cells may have a role in the protection against CVB3 infection.
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Figure 4. Evaluation of virus-specific T cell responses in infected animals. (a) Proliferative response.
A/J mice were infected with CVB3, and at termination on day 21 post-infection, splenocytes were
stimulated with or without VP1 681–700, VP1 721–740 and VP1 771–790 or control (RNase 43–56)
for 2 days, and after pulsing with 3[H] thymidine for 16 h, proliferative responses were measured
as cpm. Data sets obtained from three individual experiments each involving six to eight mice are
shown. (b) Antigen-specificity. Splenocytes from CVB3-infected mice were stimulated with indicated
VP1 peptides and maintained in medium containing IL-2 for a week. Viable cells were harvested
between days 7–10 post-stimulation and stained with indicated IAk/tetramers, anti-CD4 and 7-AAD.
After acquiring the cells by flow cytometry, tetramer positive cells were analyzed in the live (7-AAD¯)
CD4 subset using FlowJo software. Representative flow cytometric dot-plots for specific and control
tetramers are shown in the left panel. Data sets obtained from three individual experiments, each
involving six to eight mice are indicated in the right panel. RNase 43–56, control. (c) Cytokine analysis.
Splenocytes from the CVB3-infected mice were stimulated with or without the indicated peptides.
Supernatants collected on day 3 post-stimulation were analyzed for indicated cytokines by cytokine
bead array. Data from three individual experiments, each involving six to eight mice, are shown.
* p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, and **** p ≤ 0.0001.
3.5. Multiple Serotypes of CVB Can Potentially Induce Similar T Cell Responses
To determine whether the T cell epitopes identified within the CVB3 VP1 can also be used to
evaluate T cell responses in other serotypes, we compared the amino acid sequences of VP1 681–700,
VP1 721–740 and VP1 771–790 between the six serotypes of CVB. These analyses revealed identities
with a range of 65% to 85% for VP1 681–700, 75% to 90% for VP1 721–740 and 75% to 95% for VP1
771–790 (Figure S3, left panel). We also localized these epitopes in the VP1 capsid protomers within
the viral canyon by using the three dimensional structure of CVB3 (Figure S3, top and bottom right
panel) [40]. The data imply that some of these epitopes can potentially interact with the host receptor,
coxsackievirus-adenovirus receptor, leading to the induction of immune response, if immune cells are
targeted. Since we had access to CVB4, the serotype implicated in the T1D [41], we asked whether the
CVB4 infection can also lead to the induction of VP1-specific T cell responses. First, we established an
infection model in A/J mice, since CVB4 infection has not been tested in this mouse strain, and a viral
dose of 2,000 TCID50 was found to induce mainly pancreatitis and mild myocarditis in this mouse
strain. Clinically, the infected animals showed progressive loss of body weight beginning from day 3
and continued for up to day 16 post-infection (Figure 5a), whereas mortalities were noted in 42% of
animals (Figure 5b). Histologically, heart and pancreatic sections from naïve animals did not reveal any
lesions as expected. However, 33% of animals infected with CVB4 had mild myocarditis, and heart
sections revealed infiltrations of mononuclear cells (MNCs) and histiocytes (Figure 5c and Table 2, top
panel). In contrast, 92% of CVB4-infected animals showed pancreatic involvement, and acinar atrophy
and inflammation were detected in 83% and 50% of animals as prominent features, whereas necrosis
was noted in 17% of animals (Figure 5c and Table 2, bottom panel).
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were infected with or without CVB4 and their body weights were noted up to 16 days post-infection.
(b) Survival rates. The above mice were monitored for mortality post-infection and their survival
rates were calculated. Data from two individual experiments, each involving four to eight mice are
shown. (c) Histopathology. Hearts and pancreata collected at termination on day 16 post-infection
with CVB4 wer evalu ted for infla matory changes. W ile, eart (i) and pancreatic (ii) sections
from control group were nor l, sections from CVB4-infected mice had hemorrhagic necrosis, fibrosis,
mineralization and inflammation in heart (iii), and atrophy (iv) and inflammation (v) in the pancreas.
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Table 2. Histological evaluation of hearts and pancreata in naïve and CVB4-infected mice.
Parameters Naïve CVB4
Heart
Incidence 0/4 (0.0) 4/12 (33.3)
Mortality 0/4 (0.0) 5/12 (41.7)
Myocardial lesions 0.0 (0.0) 10.0 ± 1.2
Pancreas
Incidence 0 (0.0) 11/12 (91.7)
Atrophy 0 (0.0) 10/12 (83.3)
Inflammation 0 (0.0) 6/12 (50.0)
Necrosis 0 (0.0) 2/ 2 (16.7)
Mineralization 0 (0.0) 0/12 (0.0)
() indicates percentages.
We then asked whether VB4 infectio can lead to VP1-specific T cell responses similar
to CVB3 infection. This was investigated by harvesting the splenocytes from CVB4-infected
animals, and evaluated their response to VP1 681–700, VP1 721–740 or VP1 771–790 based on
3[H] thymidine-incorporation assay. The data indicate that the T cell responses were noted
predominantly for VP1 721–740 (p ≤ 0.01), whereas no significant responses were noted for VP1
681–700 or VP1 771–790 (Figure 6a). The responses were specific as the cells did not respond to control
(RNase 43–56). To further evalu te their antigen-spec ficity, we used MHC class II (IAk) tetramers
for VP1 681–700, VP1 721–740 or VP1 771–790 and stained the lymphocytes stimulated with the
corresponding peptides. The flow cytometric analysis revealed staining for VP1 681–700 and VP1
721–740 tetramers, and their respective staining intensities were 2.9% and 2.2% with an increase of ~4
to 7-fold over control tetramers (RNase 43–56) (Figure 6b). Expectedly, however, the staining obtained
with VP1 771–790 tetramers was low over control (~1.3-fold). Additionally, by evaluating cytokine
responses, we found that the culture supernatants obtained from VP1 721–740-stimulation had IFN-γ
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(116 ± 57 pg/mL). A similar trend was noted with VP1 681–700, but not for VP1 771–790 (Figure 6c).
Conversely, none of the other cytokines (IL-2, IL-6, IL-10, IL-17A and TNF-α) were found elevated in
any of the culture supernatants as compared to medium control. However, IL-4 secretion was lacking
in all of them. Taken together, the data suggest that the anti-viral T cell responses in CVB4 infection can
be captured with the assays developed for VP1 721–740, and the next best candidate is VP1 681–700.
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Figure 6. Evaluation of antigen-specific T cell responses in CVB4 infected mice: (a) Proliferative response.
A/J mice were infected with CVB4, and at termination, splenocytes were stimulated with or without VP1
681–700, VP1 721–740 and VP1 771–790 or control (RNase 43–56) for 2 days, and after pulsing with 3[H]
thymidine for 16 h, proliferative responses w re measured as cpm. Repres ntative data set obtained
from two individual experiments each involving four to eight mice are shown. (b) Antigen-specificity.
Splenocytes from CVB4-infected mice were stimulated with indicated peptides and maintained in
medium containing IL-2 for a week. Cells harvested between days 7–10 post-stimulation were
stained with the indicated IAk/tetramers, anti-CD4 and 7-AAD. After acquiring the cells by flow
cytometry, tetramer positive cells were analyzed in the live (7-AAD¯) CD4 subset using FlowJo software.
Representative flow cytometric dot-plots for specific and control tetramers are shown in the left panel.
Data sets obtained from three individual experiments, each involving four to eight mice are indicated
in the right panel for each tetramer reagent. RNase 43–56, control. (c) Cytokine analysis. Splenocytes
from the CVB4-infected mice were stimulated with or without the indicated peptides. Supernatants
were collected on day 3 post-stimulation and were analyzed for cytokines by cytokine bead array. Data
from three individual experiments each involving four to eight mice are shown. * p ≤ 0.05, ** p ≤ 0.01,
and **** p ≤ 0.0001.
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4. Discussion
In this study, we describe the identification of three T cell epitopes within the CVB3 VP1 that can
be used to evaluate antigen-specific T cell responses in CVB infections caused by multiple serotypes.
CVB3 VP1 has been shown to contain several immunogenic epitopes [42], but it was unknown whether
active infection with CVB3 can lead to the generation of virus-reactive T cell responses. Similarly, their
antigen-specificity remained uninvestigated. Furthermore, it is well known that multiple serotypes of
CVB such as CVB3 and CVB4 can induce similar diseases such as myocarditis and pancreatitis [43–46].
Therefore, development of tools common to multiple serotypes may be helpful to analyze immune
responses in such infections. To this end, we made an effort to identify the T cell epitopes with an
intent to evaluate antigen-specific T cell responses in infections caused by CVB3 and CVB4, since these
serotypes are commonly implicated in the causation of DCM and T1D, respectively [5,41].
Our investigations involved the use of A/J mice that are susceptible for CVB3 infection. To identify
the T cell epitopes, we created the overlapping peptide library consisting of 30 peptides, and their
ability to stimulate splenocytes from CVB3 infected animals. This approach was helpful since we could
narrow down to three peptides (VP1 681–700, VP1 721–740 and VP1 771–790) as potential candidates by
eliminating 27 other peptides as non-stimulators of T cell responses. By reasoning that these epitopes
could be naturally presented by the APCs in vivo, we chose them for further characterization.
Furthermore, we ascertained that CD4 T cells, but not CD8 T cells, respond to VP1 epitopes with a
tendency for proliferative responses to be more for VP1 681–700 and VP1 721–740 followed by VP1
771–790. Additionally, by using MHC class II dextramers, we verified that T cell responses induced by
each peptide were also antigen-specific. However, the MHC class II (IAk)-binding assay revealed that
VP1 681–700 was found to be a poor binder, yet it induced good T cell responses. A/J mice express
two MHC class II alleles namely, IAk and IEk [23,47], and it is possible that VP1 681–700 may bind
IEk molecule, which we have not investigated here. Alternatively, it is possible that the autoantigens
that bind poorly to MHC molecules can still elicit immune response as reported for myelin basic
protein [48]. On the other hand, VP1 771–790 in spite of being a good MHC-binder, induced relatively
moderate proliferative response. Thus, our data suggest that variations in the MHC-binding affinity of
T cell epitopes intramolecularly, as in the case of VP1, may or may not influence the T cell responses.
In such instances, determination of T cell responses for multiple epitopes may be helpful. Since all the
three VP1 epitopes induced T cell responses in the immunization settings, we sought to enumerate the
frequencies of antigen-specific CD4 T cells in CVB3 infection by creating IAk tetramers for VP1 681–700,
VP1 721–740 and VP1 771–790. We noted detection of CD4 T cells specific to VP1 721–740 consistently,
more than VP1 681–700, but VP1 771–790-specific CD4 T cells were low as evaluated by MHC tetramer
staining. Nonetheless, all three epitopes induced IFN-γ responses. Furthermore, production of IFN-γ
as in the case of VP1 771–790, but the absence of significant expansion of antigen-specific T cells, may
mean that cytokines might have been produced from non-antigen-specific T cells through, potentially,
bystander activation [49]. Thus, our data support a notion that evaluation of antigen-specific T cell
responses by different assays can yield data that may or may not complement with each other.
Finally, we expanded our observations to ask a question whether the VP1 epitopes that we have
identified can be used to evaluate T cell responses in other serotypes of CVB. We addressed this
question by establishing CVB4 infection model in A/J mice, in which the virus was found to induce
mainly pancreatitis, whereas myocarditis was mild. In this setting, we noted the virus-reactive T cell
responses to be dominant mainly for VP1 721–740 and VP1 681–700. However, by relating the cytokine
production, particularly IFN-γ, with MHC class II tetramer staining analysis, it was apparent that
VP1 721–740-reactivity can be considered as a reliable candidate. Previous reports provide evidence
for the occurrence of T cell responses to structural (VP1 to VP3) and non-structural (P2C) proteins of
CVB4 in the T1D patients, suggesting the existence of T cell epitopes in these proteins [50]. Therefore,
it is possible that other VPs (VP2 and VP3) may also encompass T cell epitopes, which we have
not investigated here. Nonetheless, if the objective is to investigate antigen-specific, anti-viral T cell
responses experimentally, then VP1 721–740 can be used as a primary candidate.
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In summary, we have identified three T cell epitopes, and at least one epitope, VP1 721–740, can
be used to evaluate antigen-specific, T cell responses both by proliferation assay and also by tetramer
staining at a single cell level by flow cytometry in CVB infections caused by more than one serotype.
Here we have provided evidence for two serotypes namely CVB3 and CVB4, and because both CVB3
and CVB4 viruses have been implicated in the causation, respectively, in viral myocarditis/DCM and
T1D, and both infections induce similar T cell responses, we propose that the VP1 721–740 and VP1
681–700 specific MHC class II/IAk tetramers can be used as helpful tools to analyze the frequencies of
antigen-specific T cells in CVB infection or vaccine studies involving these serotypes. Translationally,
whether these epitopes can be used to analyze T cell reactivity in human settings needs detailed analysis.
Nevertheless, we performed bioinformatics analysis using immune epitope database (IEDB) [51],
leading us to identify 3 to 10 putative epitopes within VP1 681–700, VP1 721–740 or VP1 771–790
that can potentially bind several HLA class I and class II alleles (Table S1). Since humans are the
natural hosts for CVB infections [52], and mouse models are commonly employed to understand the
disease pathogenesis and antiviral immune mechanisms of these infections, the availability of our tools
described in this study may be helpful to evaluate T cell responses in various experimental models.
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Abbreviations
DCM Dilated cardiomyopathy
CVB Coxsackievirus B
T1D Type 1 diabetes
MHC major histocompatibility complex
CPE cytopathic effect
RNase bovine ribonuclease
HEL hen egg lysozyme
APCs antigen presenting cells
PBS phosphate-buffered saline
LNCs lymph node cells
EMEM Eagle’s minimum essential medium
FBS fetal bovine serum
3[H] tritiated-thymidine
Cpm counts per minute
HLA human leukocyte antigen
IEDB immune epitope database
IL Interleukin
7-AAD 7-aminoactinomycin-D
IFN interferon
VP viral protein
TMEV Theiler’s murine encephalomyelitis virus
DELFIA dissociation-enhanced lanthanide fluoro immuno assay
Th T helper
CLIP class II invariant chain-associated peptide
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TNF tumor necrosis factor
MBP myelin basic protein
SA streptavidin
CFA Complete Freund’s adjuvant
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